Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind study
Kim Papp, Richard B. Warren, Lawrence Green, Kristian Reich, Richard G. Langley, C. Paul, Akihiko Asahina, Lynne Johnson, Vipin Arora, Olawale Osuntokun, Mark Lebwohl
Topics & Concepts
SecukinumabMedicinePlaceboPsoriasisPsoriasis Area and Severity IndexClinical trialInternal medicinePlaque psoriasisAdverse effectSurgeryDermatologyPsoriatic arthritisPathologyAlternative medicinePsoriasis: Treatment and PathogenesisSpondyloarthritis Studies and TreatmentsDermatology and Skin Diseases